Abstract
Introducción: El aumento de la resistencia a antibióticosrepresenta una amenaza para la salud pública al poner en riesgoel tratamiento futuro de las infecciones bacterianas. Este estudiotiene como objetivo describir el cumplimiento de las recomendaciones del Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) de la Organización Mundial de la Salud (OMS), en España y Dinamarca, en cuanto al uso ambulatoriode Critically Important Antimicrobials (CIA), así como analizarla relación entre éste y las resistencias bacterianas a ellos.
Material y métodos: Los sistemas Antimicrobial consumption interactive database (ESAC-Net) y Antimicrobial resistanceinteractive database (EARS-Net) aportaron el consumo ambulatorio (2010-2013) de los CIA (fluoroquinolonas, macrólidos ycefalosporinas de 3ª y 4ª generación) y los porcentajes de a islamientosde los principales patógenos causantes de serias infecciones, resistentes a estos agentes, en ambos países.
Resultados: En España, el uso de cefalosporinas y fluoroquinolonas, así como los porcentajes de bacterias resistentesa estos antibióticos son elevados, y superiores a los recogidosen Dinamarca. Aunque el consumo de macrólidos en ambospaíses es similar, la proporción de Streptococcus pneumoniae resistente a macrólidos es mayor en España.
Conclusión: La elevada utilización de agentes CIA enatención primaria en España se aleja de las recomendaciones de la OMS de limitar su uso. Además tiene como consecuenciaunas elevadas tasas de resistencias bacterianas, que son másmoderadas en Dinamarca.
Introduction: Increasing antibiotic resistance represents a major public health threat that jeopardises the future treatment of bacterial infections. This study aims to describe the adherence to recommendations proposed by the World Health Organization (WHO) Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR), in Spain and Denmark, and to analyse the relation between the outpatient use of Critically Important Antimicrobials (CIA) and the bacterial resistance rates to these agents.
Material and methods: The Antimicrobial consumption interactive database (ESAC-Net) and Antimicrobial resistance interactive database (EARS-Net) provided data on outpatient use (2010-2013) of CIA (fluoroquinolones, macrolides, and 3rd and 4th generation cephalosporins) and the percentages of isolates of the main pathogens causing serious infections, resistant to these agents.
Results: The use of cephalosporins and fluoroquinolones, as well as the percentage of bacteria resistant, is higher in Spain than in Denmark. Although consumption of macrolides in both countries is similar, the proportion of streptococcus pneumoniae resistant to macrolides is significantly higher in Spain.
Conclusion: The high outpatient consumption of CIA agents in Spain deviates substantially from the WHO recommendations. Moreover, it has the effect of elevated rates of antimicrobial resistance, that are lower in Denmark.
Material y métodos: Los sistemas Antimicrobial consumption interactive database (ESAC-Net) y Antimicrobial resistanceinteractive database (EARS-Net) aportaron el consumo ambulatorio (2010-2013) de los CIA (fluoroquinolonas, macrólidos ycefalosporinas de 3ª y 4ª generación) y los porcentajes de a islamientosde los principales patógenos causantes de serias infecciones, resistentes a estos agentes, en ambos países.
Resultados: En España, el uso de cefalosporinas y fluoroquinolonas, así como los porcentajes de bacterias resistentesa estos antibióticos son elevados, y superiores a los recogidosen Dinamarca. Aunque el consumo de macrólidos en ambospaíses es similar, la proporción de Streptococcus pneumoniae resistente a macrólidos es mayor en España.
Conclusión: La elevada utilización de agentes CIA enatención primaria en España se aleja de las recomendaciones de la OMS de limitar su uso. Además tiene como consecuenciaunas elevadas tasas de resistencias bacterianas, que son másmoderadas en Dinamarca.
Introduction: Increasing antibiotic resistance represents a major public health threat that jeopardises the future treatment of bacterial infections. This study aims to describe the adherence to recommendations proposed by the World Health Organization (WHO) Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR), in Spain and Denmark, and to analyse the relation between the outpatient use of Critically Important Antimicrobials (CIA) and the bacterial resistance rates to these agents.
Material and methods: The Antimicrobial consumption interactive database (ESAC-Net) and Antimicrobial resistance interactive database (EARS-Net) provided data on outpatient use (2010-2013) of CIA (fluoroquinolones, macrolides, and 3rd and 4th generation cephalosporins) and the percentages of isolates of the main pathogens causing serious infections, resistant to these agents.
Results: The use of cephalosporins and fluoroquinolones, as well as the percentage of bacteria resistant, is higher in Spain than in Denmark. Although consumption of macrolides in both countries is similar, the proportion of streptococcus pneumoniae resistant to macrolides is significantly higher in Spain.
Conclusion: The high outpatient consumption of CIA agents in Spain deviates substantially from the WHO recommendations. Moreover, it has the effect of elevated rates of antimicrobial resistance, that are lower in Denmark.
Translated title of the contribution | Adherence to international recommendations in the fight against antimicrobial resistance: Substantial difference between outpatient consumption in Spain and Denmark |
---|---|
Original language | Spanish |
Journal | Revista Espanola de Quimioterapia |
Volume | 29 |
Issue number | 1 |
Pages (from-to) | 40-43 |
Number of pages | 4 |
ISSN | 0214-3429 |
Publication status | Published - 1 Feb 2016 |
Keywords
- Antibiotics
- CIA agents
- international comparison
- bacterial resistance
- compliance with recommendations